MassDevice.com +5 | The top 5 medtech stories for August 24, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. Syneron Candela dumps Olympic swimmer Ryan Lochte Syneron Candela this week severed its ties with Olympic swimmer Ryan Lochte, who was a spokesman for the aesthetic device company’s Gentle Hair Removal brand. “We hold our employees to high standards, and we expect the same of our business partners,” Yokneam, Israel-based Syneron Candela said. “We wish Ryan well on his future endeavors and thank him for the time he spent supporting our brand.” Read more 4. SRS Medical launches Spanner prostate device study SRS Medical Systems said today it enrolled the 1st patients in an FDA investigational device exemption study as it seeks to expand the indications for its Spanner temporary prostatic stent. The Spanner device consists of a pair of anchors and a silicone tube and is designed to reduce resistance in the bladder neck and prostatic urethra without stenting the external sphincter, SRS said. It’s blind, anesthesia-free implantation procedure is similar to that for a Foley catheter, according to the company. Read more 3. Senators press ...
The American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, presented exciting updates in urothelial carcinoma. Here, Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center,... Author: VJOncology Added: 08/21/2018
Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how MVAC is still used today, with clinical trials failing to ide... Author: VJOncology Added: 08/21/2018
Publication date: Available online 20 August 2018Source: European UrologyAuthor(s): Gianluca Giannarini, Alessandro Crestani, Vincenzo Ficarra
ConclusionsThese findings suggest that amblyomin-X is rapidly distributed to the tissues, metabolized by the liver or even kidneys, and eliminated in urine in healthy mice. There is no accumulation in any organ.
Condition: Bladder Cancer Intervention: Diagnostic Test: mass spectrometry Sponsors: University of Oklahoma; National Cancer Institute (NCI) Recruiting
Conclusions: Our results suggest thatNOS3 895G#x3e;T andCBR3 730G#x3e;A are genetic markers that can be used to predict tumor recurrence in NMIBC patients receiving intravesical instillations of THP. The effects of those 2 SNPs are independent of the EORTC scores. Further studies with larger sample sizes and longer follow-ups are needed to confirm our results.Chemotherapy 2018;63:191 –197
To assess geographic variation in cystoscopy rates among women versus men with suspected bladder cancer, lending insight into gender-specific differences in cystoscopic evaluation.
AbstractPurpose of ReviewRecent whole genome characterizations of primary human bladder cancers revealed that they can be grouped into “intrinsic” basal and luminal molecular subtypes. Here, we provide an overview of the subtypes and discuss their biological and clinical properties.Recent FindingsBasal cancers are characterized by advanced stage and metastatic disease at presentation. They tend to be enriched with squamous and small cell/neuroendocrine features and inactivating mutations and deletions ofTP53 andRB1. Basal cancers can be divided into “epithelial” and “mesenchymal” (also k...
With an estimated 79,030 new diagnoses and 16,870 deaths in 2017, bladder cancer is the 5th most common cancer in the U.S. and conveys the highest mortality among urological malignancies . Despite the significant improvement seen in cancer survival over the last three decades, racial disparities are persistent and most pronounced in Black (non-Hispanic) men and women . Black patients as compared to White (non-Hispanic) patients exhibit half the bladder cancer incidence but show significantly greater mortality.
Most bladder cancers are urothelial carcinomas. Roughly 75% of patients have nonmuscle invasive bladder cancer (NMIBC) and the remainder have muscle invasive or metastatic disease . For all stages, the 5-year relative survival is around 70% to 80% . The rate of recurrence in NMIBC ranges from 50% to 90%. In addition, 10% to 30% of NMIBC patients progress to muscle invasive bladder cancer (MIBC) requiring radical surgery . In NMIBC patients after first transurethral resection, identification of the key predictors of progression should improve overall survival by supporting the use of aggressive treatment in short-term follow-up.